Navigation Links
Lenalidomide safe as single therapy for elderly CLL patients
Date:12/8/2008

SAN FRANCISCO ― The oral medication lenalidomide is safe and well-tolerated for elderly patients with chronic lymphocytic leukemia, a group without a well-defined frontline therapy for their disease, researchers from The University of Texas M. D. Anderson Cancer Center reported today at the 50th annual meeting of the American Society of Hematology.

"Lenalidomide has a favorable toxicity profile and shows signs of activity against CLL in our phase II clinical trial to date," said study presenter Alessandra Ferrajoli, M.D., associate professor in M. D. Anderson's Department of Leukemia.

Patients start on a 5 mg dose of the drug in pill form and the dose escalates over time in 5 mg increments to a maximum of 25 mg. The median age of participants is 72. Chemo-immunotherapy therapy combinations that are effective in younger patients with CLL tend to be associated with a high rate of complications in patients older than 70, Ferrajoli said.

Of 43 patients enrolled in the study, 35 were evaluable because they had been treated for at least three months. Nineteen of these (54 percent) achieved a partial response, where the disease is diminished, 14 patients (40 percent) had stable disease and continue on therapy, and two had their CLL progress.

Lenalidomide also rapidly reduced the number of circulating lymphocytes the hallmark of the disease in the patients' blood. Ferrajoli said 47 percent achieved a blood complete response and 38 percent had at least a partial response.

Patients on the trial for at least two months were evaluated for the drug's potential side effects. Of those 39 patients, 10 (26 percent) had decreased bone marrow activity resulting in a decrease in the number of either white blood cells called neutrophils or of platelets. Three patients had infections, two had fever and one had pneumonia.

All patients registered in the study remain alive with 37 of the 43 continuing on treatment. Ferrajoli said the trial will include up to 60 patients.

Lenalidomide, a drug developed by Celgene Corp. known commercially as Revlimid, attacks both malignant cells and the cellular environment that nurtures them. The U.S. Food and Drug Administration has approved the drug for treatment of multiple myeloma and some forms of myelodysplastic syndrome.


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. SurgiQuest Announces First Single Port Procedure for Uterus and Ovary Removal Using AirSeal(TM) Access System
2. Brigham and Womens Hospital Selects SinglePointe(TM) Automated Patient-Specific Medication Management Solution from Omnicell
3. Single in the City? How the Holidays Leave the Fabulous Feeling More Like Failures
4. First and Only Single Capsule Daily Rx Prenatal Vitamin With Plant-Based DHA Now Available
5. Elseviers New Imaging Consult Features In-Depth, Authoritative Information For Diagnostic and Interventional Imaging and Procedures in a Single Online Resource
6. Study Singles Out Beachgoers Skin Cancer Risk
7. Most Single Adults Not Using Condoms
8. University Of Minnesota Gives 11,538 Flu Shots Tuesday, Shattering Guinness World Record for Most Flu Shots in a Single Day
9. New Prostrates Grown From Single Stem Cell
10. HIV Can Re-Emerge From a Single Cell
11. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase Up to $18 Million of Senior Convertible Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... , ... May 02, 2016 , ... ... in Huntington Beach, California announced today the release of Grow Healthy Vending’s newly ... is one of the fastest growing healthy vending providers in North America with ...
(Date:5/2/2016)... ... ... This week Omega Institute, a premier nonprofit educational retreat center in New York’s ... offering a record 370 in-person workshops and new online learning opportunities and live ... or need for the knowledge and skills we’ve been cultivating for nearly 40 years. ...
(Date:5/2/2016)... ... 02, 2016 , ... The 2016 World Ultimate & Guts Championship (WUGC) Mixed roster was announced ... the cut. The WUGC is being held in London, England this year from June 18-25. ... men’s division, another gold in the women’s masters division, and a silver in the women’s ...
(Date:5/2/2016)... ... May 02, 2016 , ... TeleMedCo™, ... facilities designed to automate and improve the rapid diagnosis, triage and admission of ... their platform, application, and mobile experience for the first time at GENBAND’s Perspectives16 ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... ... improve adherence, transition of care and quality outcomes, has announced its partnership with ... innovative, independent pharmacy that provides over the counter and prescription drug pharmacy services ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... 2, 2016 The global  ... 11.1 billion by 2024, according to a new ... drivers of the sonography market include expanding applications ... recommendations for periodic ultrasound screenings of the breast ... http://photos.prnewswire.com/prnh/20150105/723757 ) High Intensity Focused ...
(Date:4/29/2016)... PARIS , April 29, 2016 ... Jérôme Contamine, Directeur Financier ... la santé, publie ses résultats pour ... Financier du Groupe, Jérôme Contamine, commente ... Groupe et les perspectives pour le ...
(Date:4/28/2016)... , April 28, 2016  While Abbott,s ... complement the company,s valve repair and stent business, ... also places Abbott more firmly into patient monitoring.  ... the fastest growing device areas, with double-digit growth ... recent report,  Advanced Remote Patient Monitoring ...
Breaking Medicine Technology: